title: Use of an ophthalmic formulation of megestrol acetate for the treatment of eosinophilic keratitis in cats.
abstract: OBJECTIVE
  To evaluate a compounded ophthalmic formulation of 0.5% megestrol acetate to treat eosinophilic keratitis in cats.
  
  
  METHODS
  Prospective study.
  
  
  METHODS
  Seventeen client owned cats with eosinophilic keratitis in one or both eyes.
  
  
  METHODS
  Eosinophilic keratitis was confirmed by cytology. At each visit, fluorescein staining and photography were performed. Cats were initially treated q 8-12 h with 0.5% megestrol acetate in an aqueous base. Serum glucose was measured at the first or second reexamination.
  
  
  RESULTS
  Fifteen of 17 (88%) cats had a positive response to treatment, with 6 of 17 (35%) having complete resolution at the first reexamination (2-4 weeks). Two of 17 (12%) cats did not respond to treatment. Most cats required a treatment frequency of once daily to once weekly to maintain remission of disease. No ocular irritation or systemic side effects were noted in any cat.
  
  
  CONCLUSIONS
  The use of an ophthalmic formulation of 0.5% megestrol acetate is a viable option for treating feline eosinophilic keratitis.
authors.affiliation: Purdue University College of Veterinary Medicine, 625 Harrison St., West Lafayette, IN, 47907, USA.
authors.forename: Jean
authors.initials: J
authors.lastname: Stiles
authors.affiliation: Angell Animal Medical Center, 350 S. Huntington Ave, Boston, MA, 02130, USA.
authors.forename: Martin
authors.initials: M
authors.lastname: Coster
mesh_terms: D060433:Administration, Ophthalmic; D000818:Animals; D002371:Cat Diseases / Q000188:drug therapy* / Q000473:pathology; D002415:Cats; D004804:Eosinophils; D005260:Female; D007634:Keratitis / Q000188:drug therapy / Q000473:pathology / Q000662:veterinary*; D008297:Male; D019290:Megestrol Acetate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use*; D011372:Progestins / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies
chemical_list: D009883:Ophthalmic Solutions; D011372:Progestins; D019290:Megestrol Acetate
keywords: cat; eosinophilic keratitis; feline; megestrol acetate; proliferative keratitis